Revelation Biosciences Stock Current Valuation
| REVB Stock | USD 0.76 0.01 0.67% |
Valuation analysis of Revelation Biosciences helps investors to measure Revelation Biosciences' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Revelation Biosciences' Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 94.48, whereas Enterprise Value is projected to grow to (1.8 M). Fundamental drivers impacting Revelation Biosciences' valuation include:
Price Book 1.1922 | Enterprise Value 9.4 M | Enterprise Value Ebitda (1.02) | Price Sales 2.8821 | Forward PE 7.7942 |
Undervalued
Today
Please note that Revelation Biosciences' price fluctuation is very risky at this time. Calculation of the real value of Revelation Biosciences is based on 3 months time horizon. Increasing Revelation Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Revelation Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Revelation Stock. However, Revelation Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.76 | Real 3.41 | Target 11.45 | Hype 0.74 | Naive 0.69 |
The real value of Revelation Stock, also known as its intrinsic value, is the underlying worth of Revelation Biosciences Company, which is reflected in its stock price. It is based on Revelation Biosciences' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Revelation Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Revelation Biosciences helps investors to forecast how Revelation stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Revelation Biosciences more accurately as focusing exclusively on Revelation Biosciences' fundamentals will not take into account other important factors: Revelation Biosciences Company Current Valuation Analysis
Revelation Biosciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Revelation Biosciences Current Valuation | 9.41 M |
Most of Revelation Biosciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Revelation Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revelation Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Revelation Biosciences is extremely important. It helps to project a fair market value of Revelation Stock properly, considering its historical fundamentals such as Current Valuation. Since Revelation Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Revelation Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Revelation Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Revelation Biosciences has a Current Valuation of 9.41 M. This is 99.93% lower than that of the Biotechnology sector and 99.8% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.94% higher than that of the company.
Revelation Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Revelation Biosciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Revelation Biosciences could also be used in its relative valuation, which is a method of valuing Revelation Biosciences by comparing valuation metrics of similar companies.Revelation Biosciences is currently under evaluation in current valuation category among its peers.
Revelation Fundamentals
| Return On Equity | -2.7 | ||||
| Return On Asset | -0.51 | ||||
| Current Valuation | 9.41 M | ||||
| Shares Outstanding | 4.29 M | ||||
| Shares Owned By Insiders | 0.12 % | ||||
| Shares Owned By Institutions | 2.31 % | ||||
| Number Of Shares Shorted | 41.24 K | ||||
| Price To Earning | 8.69 X | ||||
| Price To Book | 1.19 X | ||||
| Price To Sales | 2.88 X | ||||
| Gross Profit | 90.91 M | ||||
| EBITDA | (95.21 K) | ||||
| Net Income | (120.25 K) | ||||
| Cash And Equivalents | 3.48 M | ||||
| Cash Per Share | 0.15 X | ||||
| Total Debt | 5.56 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 0.68 X | ||||
| Book Value Per Share | 0.62 X | ||||
| Cash Flow From Operations | (7.29 M) | ||||
| Short Ratio | 0.69 X | ||||
| Earnings Per Share | (17.53) X | ||||
| Target Price | 12.75 | ||||
| Beta | 0.15 | ||||
| Market Capitalization | 3.21 M | ||||
| Total Asset | 12.21 M | ||||
| Retained Earnings | (25.47 M) | ||||
| Working Capital | 6.58 M | ||||
| Net Asset | 12.21 M |
About Revelation Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Revelation Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Revelation Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Revelation Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Revelation Biosciences is a strong investment it is important to analyze Revelation Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revelation Biosciences' future performance. For an informed investment choice regarding Revelation Stock, refer to the following important reports:Check out Revelation Biosciences Piotroski F Score and Revelation Biosciences Altman Z Score analysis. For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. If investors know Revelation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revelation Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (17.53) | Return On Assets (0.51) | Return On Equity (2.70) |
The market value of Revelation Biosciences is measured differently than its book value, which is the value of Revelation that is recorded on the company's balance sheet. Investors also form their own opinion of Revelation Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Revelation Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revelation Biosciences' market value can be influenced by many factors that don't directly affect Revelation Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revelation Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revelation Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revelation Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.